***Background.*** Plazomicin is a next generation aminoglycoside that is not affected by most commonly-encountered aminoglycoside modifying enzymes and is currently being studied in a global Phase 3 trial enrolling patients with bloodstream infections or nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae. The activity of this novel agent was tested against a contemporary collection of Enterobacteriaceae from New York City.

***Methods.*** Unique patient isolates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter* spp. were gathered from 11 hospital microbiology laboratories from November 2013 through January 2014. Isolates underwent susceptibility testing by the agar dilution method according to CLSI guidelines. Cephalosporin-resistant isolates were screened for the presence of *bla*~KPC~.

***Results.*** A total of 2866 isolates of *E. coli* (two with *bla*~KPC~), 944 isolates of *K. pneumoniae* (125 with *bla*~KPC~), and 216 isolates of *Enterobacter* spp. (7 with *bla*~KPC~) were collected. Susceptibility results for gentamicin, amikacin, and plazomicin are shown in the table.

Among the 125 isolates of *K. pneumoniae* with *bla*~KPC~, the MIC~50~ and MIC~90~ values for plazomicin were 0.5 and 1 µg/ml, respectively.

                                MIC~50~   MIC~90~   Range         Percent susceptible
  ----------------------------- --------- --------- ------------- ---------------------
  *E. coli* (n=2866)                                              
  Gentamicin                    1         \>8       ≤0.25 - \>8   85%
  Amikacin                      2         4         ≤0.5 - \>64   99.5%
  Plazomicin                    1         1         0.12 - 4      
  *K. pneumoniae* (n=944)                                         
  Gentamicin                    0.5       \>8       ≤0.25 - \>8   78%
  Amikacin                      2         32        ≤0.5 - \>64   88%
  Plazomicin                    0.5       0.5       0.12 - 32     
  *Enterobacter* spp. (n=216)                                     
  Gentamicin                    0.5       2         ≤0.25 - \>8   92%
  Amikacin                      2         4         ≤0.5 - 64     97%
  Plazomicin                    0.5       1         0.25 - 4      

***Conclusion.*** Plazomicin is an investigational aminoglycoside with broad-spectrum activity against common Enterobacteriaceae, including multidrug-resistant strains of K. pneumoniae. Further studies with this agent are warranted.
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